Related Experiment Video

Updated: Sep 15, 2025

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.0K

Effect of Low-Dose Atropine on Choroidal Thickness in Children With Myopia Progression

Shrutakirty Parida1, Matuli Das2, Snehalata Dash3

  • 1Pediatric Ophthalmology, Strabismus and Neuro-ophthalmology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND.

Cureus
|July 17, 2025
PubMed

Insights

Low-dose atropine (0.01%) significantly increased choroidal thickness in children with progressive myopia. This choroidal thickening correlated with slower myopia progression, indicating a potential therapeutic benefit.

Area of Science:

  • Ophthalmology
  • Pediatric Ophthalmology
  • Myopia Control

Background:

  • Progressive myopia is a growing concern in children.
  • Choroidal thickness is a potential biomarker for myopia progression.
  • Low-dose atropine is being investigated for myopia control.

Purpose of the Study:

  • To evaluate the effect of 0.01% low-dose atropine on choroidal thickness in children with progressive myopia.
  • To compare myopia progression rates between low-dose atropine and placebo groups.
  • To assess changes in refractive error, axial length (AXL), and best-corrected visual acuity (BCVA).

Main Methods:

  • A prospective, case-control interventional study.
  • 87 children (5-16 years) with bilateral progressive myopia were randomized into two groups.
  • Measurements included spherical equivalence, AXL, and choroidal thickness at baseline and 6 months; one group received low-dose atropine, the other placebo.

Main Results:

  • Low-dose atropine significantly increased overall choroidal thickness at 3 and 6 months.
  • The increase in choroidal thickness showed a significant correlation with slower myopia progression (spherical equivalence and AXL).

Conclusions:

  • Low-dose atropine (0.01%) effectively induces choroidal thickening in children with progressive myopia.
  • This choroidal thickening is associated with a reduced rate of myopia progression.
  • Low-dose atropine demonstrates potential as a therapeutic intervention for myopia control.
Abstract

Keywords:
axial lengthbest corrected visual acuitychoroidal thicknessenhanced-depth imagingintraocular pressureoct (optical coherence tomography)retinal pigment epithelium (rpe)spherical equivalent (se)

More Related Videos

Inducement and Evaluation of a Murine Model of Experimental Myopia07:20

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

10.1K
Determining Gender-Based Differences in Retinal and Choroidal Thickness in Underweight Individuals via Swept-Source Optical Coherence Tomography03:35

Determining Gender-Based Differences in Retinal and Choroidal Thickness in Underweight Individuals via Swept-Source Optical Coherence Tomography

Published on: December 1, 2023

381

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
579
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
697
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.6K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
843
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
775